Literature DB >> 25988640

To stop or not?

Berend Mets1.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 25988640     DOI: 10.1213/ANE.0000000000000758

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


× No keyword cloud information.
  5 in total

1.  Icatibant as an early rescue therapy in hypovolemic shock with converting enzyme inhibitor treatment.

Authors:  Hélène Charbonneau; Marie Buléon; Benoit Richard; Nicolas Mayeur
Journal:  Crit Care       Date:  2017-11-02       Impact factor: 9.097

2.  Can ACE-I Be a Silent Killer While Normal Renal Functions Falsely Secure Us?

Authors:  Ahmed Abdelaal Ahmed Mahmoud; Mark Campbell; Margarita Blajeva
Journal:  Case Rep Anesthesiol       Date:  2018-07-09

3.  The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial.

Authors:  Satyajeet Misra; Satyen Parida; Raj Sahajanandan; Bikram Kishore Behera; Muthapillai Senthilnathan; Ramamani Mariappan; Tony Thomson Chandy
Journal:  Trials       Date:  2022-08-17       Impact factor: 2.728

4.  Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial).

Authors:  Matthieu Legrand; Emmanuel Futier; Marc Leone; Benjamin Deniau; Alexandre Mebazaa; Benoît Plaud; Pierre Coriat; Patrick Rossignol; Eric Vicaut; Etienne Gayat
Journal:  Trials       Date:  2019-03-05       Impact factor: 2.279

5.  A randomized controlled trial comparing methohexital and propofol for induction in patients receiving angiotensin axis blockade.

Authors:  Anthony Bonavia; Thomas Verbeek; Sanjib Adhikary; Allen Kunselman; Arne Budde; Jerome Lyn-Sue; Berend Mets
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.